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Abstract
Oral delivery is the most common and preferred route of drug administration 
due to its convenience and ease of administration. However, various factors such 
as poor solubility, low dissolution rate, stability, and bioavailability of many drugs 
remain an ongoing challenge in achieving desired therapeutic levels. The delivery of 
drugs must overcome various obstacles, including the acidic gastric environment, 
the presence of the intestinal efflux and influx transporters and the continuous 
secretion of mucus that protects the gastrointestinal tract (GIT). As the number 
and chemical diversity of drugs has increased, various strategies are required to 
develop orally active therapeutics. One of the approaches is to use chitosan as a 
carrier for oral delivery of peptides, proteins as well as vaccines delivery. Chitosan, a 
non-toxic N-deacetylated derivative of chitin appears to be under intensive progress 
during the last years towards the development of safe and efficient chitosan-based 
drug delivery systems. This polymer has been recognised as a versatile biomaterial 
because of its biodegradability, biocompatibility, and non-toxicity. This chapter 
reviews the physicochemical characteristics of chitosan and the strategies that have 
been successfully applied to improve oral proteins, peptides, and vaccines bioavail-
ability, primarily through various formulation strategies.
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1. Introduction
The extent of drug bioavailability has been shown to be influenced by the route 
of drug administration. Oral drug route needs travelling through the continuous 
passageway of the GIT, which makes them susceptible to the harsh environment of 
GIT. Drugs intended for administration via this route can be formulated in a variety 
of dosage forms, such as tablets, capsules, solutions, and powders.
Due to its high patient compliance and ease of administration, the oral route 
of administration is preferred among other routes. Self-administration is possible 
with great compliance and reduced risk in developing systemic side effects, which is 
the major concern in the parenteral route [1]. Despite that, the oral delivery system 
approaches for certain drugs are challenging, especially the delivery of peptide 
drugs and vaccines [2].
The normal physiological functions of GIT are to digest food and to interfere 
with pathogen entry. These functions need to be considered as peptide drugs 
and vaccines tend to be digested together with food in the presence of digestive 
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enzymes. The highly acidic pH in the stomach and the presence of proteolytic 
enzymes such as protease and pepsin can cause protein degradation [1].
Furthermore, they will have difficulties in permeating the physical barrier of the 
mucus lining, which prevents pathogenic substances from penetrating the cell [3]. 
Owing to these challenges, protein and peptide drugs are suitable to be administered 
via parenteral routes such as intravenous or subcutaneous injection [4]. However, 
these routes require frequent administration with long-term use which will develop 
patient incompliance to medication [4]. In such a manner, the approach to improve 
the oral delivery of peptide drugs and vaccines by using suitable polymers are 
needed to enhance drug effectiveness and patient compliance.
Chitin is the second most abundant polysaccharide present in nature. However, 
it has more applications when converted to chitosan by partial deacetylation under 
alkaline conditions [5]. Chitosan is a positively charged polymer that can improve 
the bioavailability of the oral drug delivery system. It has been used to improve the 
formulation of peptide drugs, resulting in enhanced cell permeability, which allows 
an adequate therapeutic concentration of drugs into the systemic circulation [6].
For protein and peptide therapeutics, factors such as poor permeability, luminal, 
brush border, cytosolic metabolism, and hepatic clearance mechanisms result in 
their poor bioavailability from oral and non-oral mucosal routes [7]. Oral vaccina-
tion is prone to reduce the adequacy of vaccine to be recognised by the immune 
system due to the presence of gut microbiota and intestinal barrier. Peptide drugs 
and vaccines can be protected from the degradative barrier of the GIT by encap-
sulating the drugs into the polymeric chitosan as potential carrier material. The 
development of nanotechnology, such as nanoparticle systems to transport peptide 
drugs through the epithelial membrane has been established [6, 8]. Besides, the 
modification of chitosan is needed to exert its function as a polymer and to protect 
the drug from enzymatic degradation [9].
This work reviews the physicochemical properties and numerous applications of 
chitosan, describes its release mechanisms, challenges in oral peptides and vaccines 
delivery, and strategies to overcome these barriers to improve oral peptides and 
vaccines bioavailability.
1.1 Chitosan
Chitosan is a strong base with linear polysaccharides consisting of 
D-glucosamine, which contains amino groups [10]. The hydrolysis of chitin will 
produce chitosan through alkaline hydrolysis or N-deacetylation (Figure 1). 
Due to protonable amino groups presence in chitosan, this polymer can be easily 
Figure 1. 
The N-deacetylation of chitin into chitosan.
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dissolved in pH below 6.3. However, both chitosan and chitin are insoluble in an 
aqueous medium.
Chitin or chitosan is highly available from different species of shrimps, prawns 
and crabs. These seafood shells release chitosan, which shows properties of antimi-
crobial and antioxidant activity.
1.2 Characterisation of chitin and chitosan
One of the differences between chitosan and chitin is the presence of amino 
groups. Amino group in chitosan exhibits high solubility in acidic medium and able 
to form complexes with metal ions. These positive charges interact with drugs and 
physiological barriers in the GIT, which is useful in the formulation design of the 
drug delivery system [9].
Some factors affect chitosan properties, including the degree of deacetylation, 
degree of substitution, and molecular weight [9, 11]. These factors should be 
considered before using chitosan as a polymer in a drug delivery system. Most of 
the chitosan applications are affected by these factors through intermolecular or 
intramolecular hydrogen bonds [12].
1.2.1 Degree of deacetylation and molecular weight of chitosan
The degree of chitosan deacetylation will affect its biological activity, including 
swelling rate, molecular weight, crystallinity and polydispersity. The deacetylation 
process leads to the protonation of the amino groups [13]. A highly positive charge 
will improve the activity of chitosan as mucoadhesive permeation enhancing [14] 
and haemostatic agent [15]. Sometimes, the degree of deacetylation can be used to 
estimate the water solubility of chitosan [11] as shown in Table 1.
The degree of deacetylation can influence the particle size and molecular weight 
of chitosan [13]. The removal of the acetyl group in the structure of chitosan or 
chitin from deacetylation reduces the interaction between molecules. A low number 
of acetyl groups minimises the chain length, thus reducing the molecular weight of 
the polymer [16].
The molecular weight of the polymer will influence the degree of swelling 
[17]. High molecular weight chitosan (HMWC) tends to have a higher cross-link-
ing ability. Therefore, the drug-coated with HMWC tends to release more slowly 
[18]. This characteristic is favourable in sustained-release oral drug delivery.
Generally, the lower the molecular weight, the higher solubility of chitosan is 
obtained [13, 19]. HMWC appears in α-chitin crystalline or antiparallel structure. 
The structure forms after the release of water, which leads to the loss of entropy 
during aggregation of the polymeric chain [13]. This phenomenon results in the 
loss of Gibbs free energy. Gibbs free energy (G) is a way to predict the amount of 
Degree of deacetylation Level Water solubility
55–70% Low Completely insoluble
70–85% Middle Partly dissolved
85–95% High Good solubility
95–100% Ultrahigh Completely soluble
Table 1. 
Relationship between degree of deacetylation of chitosan and their water solubility [11].
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usable energy in the system. Loss of energy means the reaction in the system tends 
to be spontaneous.
The α-chitin crystalline form exhibit lower water solubility as compared to 
β-chitin. The shorter polymeric chain of low molecular weight chitosan (LMWC) is 
unlikely to aggregate [11]. Interaction between molecules declines due to the forma-
tion of the hydrogen bonds is limited. A short chitosan chain contains a low number 
of amino groups [20].
1.2.2 Crystalline structure
Chitin exists in three different polymorphic forms, which are α-chitin, β-chitin, 
and γ-chitin (Figure 2). The interaction between C═O⋯NH and C═O⋯OH main-
taining the strength of the polymeric network chain [13]. α-chitin appears in its 
antiparallel structure and the chain is interacting through both inter-and intramo-
lecular hydrogen bond. β-chitin has a parallel structure, which leads to the forma-
tion of the intramolecular hydrogen bond. γ-chitin consists of both antiparallel and 
parallel structure, as it is the combination of α-chitin and β-chitin [21].
β-Chitin exhibits better water solubility but less common as compared to 
α-chitin [14]. It has been shown that α-chitosan has a higher crystallinity index 
as compared to β-chitin. However, the crystallinity index for both forms is lower 
than the raw chitosan [21]. The crystallinity index will increase when the degree of 
deacetylation of chitosan increases [16].
The β-chitin has a high affinity to the organic solvent due to its structural flex-
ibility [14]. It exhibits higher reactivity than α-chitosan due to a lack of hydrogen 
bond. This form has a high capability to swell between crystalline structures while 
losing its crystalline fraction [21]. The swelling of β-chitin sometimes disrupts the 
polymeric chain and crystalline structure.
Figure 2. 
The different conformational structure between α-chitin, β-chitin and γ-chitin (adapted from [14]).
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1.2.3 Polydispersity and particle size of chitosan
The particle size of chitosan plays a major role in developing an efficient carrier 
for peptide drugs [22]. Monodisperse preparation of nanoparticles is desirable to 
provide better bioavailability and low toxicity [23]. Polydispersity leads to a larger 
size distribution, which interferes with the tendency for the nanocarrier to accumu-
late in the target tissue [23].
Polydispersity describes the degree of non-uniformity of size distribution 
between molecules due to the aggregation or agglomeration of the polymeric 
network. It can be estimated using the polydispersity index (PDI), where the ideal 
index for chitosan nanoparticles is below 0.3 [22, 23]. The degree of deacetylation 
and molecular weight of chitosan have been proven to influence the polydispersity 
of the system [24].
PDI increases with an increase in molecular weight. However, it decreases as the 
degree of deacetylation increases [23]. The increase of amino group protonation 
and removal of the acetyl group from chitosan structure lead to the enhancement 
of repulsive forces between molecules and stretch the chitosan to become larger in 
size [11, 24]. Therefore, the development of chitosan with the optimum degree of 
deacetylation is needed to minimise the risk of polydispersity. This can be achieved 
by modifying the time and temperature of the de-N-acetylation process [18].
The degree of entanglement for HMWC nanoparticles is higher than LMWC. 
Therefore, HMWC nanoparticle has a high tendency to aggregate with each other 
and disrupt the uniformity of the system [25]. However, LMWC cannot be loaded 
into nanoparticles with smaller size due to its limitation to entangle to the structures 
of the system [26]. Therefore, maintaining the particle size of the chitosan is crucial 
in the development of a chitosan nanoparticle.
1.3 Modification of chitosan as biomaterial
Modified chitosan shows greater advantages as compared to unmodified chitosan. 
The modification of chitosan either chemically or physically may improve its solubil-
ity, properties of gelling, and biocompatibility. This modification can be done through 
cross-linking or substitution [27]. The presence of the various reactive functional 
groups in the chitosan structure makes it available in many derivatives with different 
stability properties.
1.3.1 Quaternisation
A quaternary ammonium salt is a hydrophilic group with a permanent posi-
tive charge. Therefore, quaternary chitosan does not need an acidic condition to 
undergo protonation [12, 28]. It allows chitosan quaternary ammonium salts to be 
soluble in both acidic and basic pH. This is a good approach to increase chitosan 
solubility in water [28].
The high strength of the positive charge will weaken the hydrogen bond. 
However, this activity depends on the degree of substitution. The higher the degree 
of substitution, the higher the water solubility of chitosan. This will improve the 
quality of chitosan to act as a mucoadhesive agent that aids the penetration into 
mucus [29].
Trimethyl chitosan (TMC) is an example of a chitosan derivative from quater-
nisation. This modification is effective in enhancing the bioavailability of anti-
bacterial drugs with antibacterial properties. Moreover, quaternised chitosan also 
exhibits antibacterial properties by the interaction of its positive charge with the 
negative charge of Gram-negative bacteria [28–30].
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1.3.2 Sulfonated chitosan
Sulfonated chitosan is water-soluble anionic chitosan, which was derived with 
N-benzyl disulfonated derivative [31]. This modification of chitosan has been 
shown to be effective, not only as antiviral and antibacterial but also as anticoagu-
lant properties. Sulfonated chitosan interferes with the interaction between the 
envelope glycoprotein (gp120) and its receptor on the CD4 cells’ surface. Therefore, 
It inhibits the replication of HIV [32].
Sulfonated chitosan has been developed to carry anticoagulant drugs such as 
reviparin and enhance the anticoagulant activity. Sulfonated chitosan nanoparticles 
interact with factor Xa and inhibit their function in the blood clotting mechanism 
[31, 33]. Low molecular weight sulfoethyl chitosan acts as capping of nanopar-
ticles [33]. A capping agent is needed in the nanoparticulate system to prevent 
agglomeration.
Amphotericin B is used to treat fungal infection by binding to ergosterol on the 
cell membrane of fungal. It depolarises the membrane and alters its permeability 
[34]. Sulfonated chitosan has been used in the formulation of amphotericin B to 
reduce the side effects of the drug by making sure the drug specifically targets the 
ergosterol of fungal [35].
1.3.3 Thiolation
The structure of mucin that coats the intestinal epithelial cell contains the 
cysteine-rich domain. This domain easily forms a disulfide bond with a thiolated 
derivative of chitosan. The bond formations increase the residence time for the 
chitosan to the mucus and increase the mucoadhesive property of the chitosan 
[30, 36]. When chitosan covalently bonded with any thiolated moiety, water-
soluble carbodiimide is required as a cross-linker [30]. Carbodiimide increases the 
number of thiol groups. This enhances the immobilisation phenomena, which is 
the formation of disulfide bonds due to the activation of carboxylic groups.
The thiolation of TMC with the conjugation of cysteine residue increases 
the strength of covalent bonding between mucin. The covalent bond forma-
tion of chitosan with thioglycolic acid (TGA) is an effective carrier in delivering 
trimethoprim for urinary tract infection [37]. The preparation of chitosan-TGA 
nanoparticles should be stabilised by covalent cross-linking with polyanion, such 
as tripolyphosphate [38]. The cross-linking minimise the risk of particle aggrega-
tion, increases the disulfide bond, and strengthens the mechanical force between 
networks, which allows trimethoprim to be released slowly [37].
The conjugation of chitosan with glutathione will protect peptide drugs from 
aminopeptidase in the GIT [39]. Glutathione has thiol groups which exhibit strong 
electron-donating properties. It forms an α-peptide bond with cysteine moiety of 
aminopeptidase [30]. Glutathione also acts as an antioxidant which reduces oxidative 
stress and increases the adhesion of formulation to the cell [30].
1.3.4 Carboxy alkyl chitosan
The poor water solubility of chitosan makes them less effective as a permeation 
enhancer. The addition of the carboxyalkyl group will transform the molecule into 
amphoteric in nature and allow them to react in both basic and acidic conditions 
[40]. The interaction between the carboxyl group and the primary amino group of 
chitosan exhibits a promising approach in developing controlled drug release.
The Schiff base reactive gives rise to the formation of the N-carboxymethyl 
derivative of chitosan [41]. This modification of chitosan has been shown to improve 
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the absorption of low molecular weight heparin (LMWH). After coating into 
polydopamine, the conjugation of LMWH with carboxymethyl chitosan into poly-
urethane substrate shows excellent hemocompatibility of heparin. This modification 
enhances the bioavailability and improves the anticoagulant effect of heparin [42].
Propranolol hydrochloride has a short half-life and requires every 6 to 8 hours 
in a divided daily dose. The use of carboxymethyl chitosan will coat the drug with 
a polymer matrix. It controls the release of drug with zero-order kinetics, allowing 
the constant amount of drug will be eliminated per unit time. The hydration of 
carboxymethyl chitosan will form a gel layered around the drug, which essential in 
drug release [43, 44].
1.4 Release mechanisms of chitosan nanoparticle
The release of drugs from the chitosan nanoparticle is influenced by the hydro-
philicity of chitosan and pH of the swelling solution. Chitosan release mechanism 
involves swelling, diffusion of drugs through the polymeric matrix and polymer 
erosion [45]. Due to the hydrophilicity of chitosan, chitosan nanoparticles exhibit 
pH-dependent drug and controlled drug release system [6].
Acid and base act as catalysts in the degradation of polymers [46]. Therefore, the 
behaviour of swelling and the amount of drug released is highly dependent on the 
pH of the swelling solution. Hence, a modified drug release can be achieved [46]. 
When polymers get into contact with an aqueous medium, the water will diffuse 
into the polymer until the polymer swells (Figure 3).
Figure 3. 
The swelling of swellablepolymers in aqueous medium (adapted from [49]).
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The polymeric chitosan chain will start to detangle. The swelling polymer will 
form pores which allow drugs to diffuse out of the nanoparticulate system [6, 43, 47]. 
Therefore, the water solubility of chitosan is crucial in the mechanism of drug release 
from the nanoparticulate system.
1.5 The use of chitosan to improve drug delivery system
Oral drug administration is the most convenient route, especially among the 
elderly and children. Unfortunately, some drugs and vaccines cannot withstand 
the physiological barrier of GIT. In the presence of mucus, proteolytic enzymes, 
and first-pass metabolism by the liver, drugs tend to be degraded or converted 
into inactive metabolites [48]. Some drugs will be excreted in the urine lead to low 
bioavailability.
Due to the challenges aforesaid, chitosan and its derivatives have been used 
in the development of nanotechnology to improve oral drug delivery [25, 30]. It 
encapsulates drugs to protect them from degradation in the GIT environment. 
As a consequence of its excellent biodegradable, biocompatibility, and non-toxic 
properties, chitosan promotes a stimuli-responsive release of drugs. It allows active 
ingredients to be released from the formulation in a controlled manner, specifically 
in enteric-coated drugs [38, 43].
Due to its antimicrobial properties, it was used in the delivery of oral antibiotics to 
eradicate Gram-negative bacteria such as E. coli [49]. This approach not only improves 
the bioavailability of antibiotic in the body but also indirectly enhance the effective-
ness of the drugs in eradicating the infection [15].
2. The properties of protein and peptide
A peptide is made up of short polymers of ⍺-amino acid, which is around 20 to 
50 amino acids. The function of small peptides depends on the functional group 
of various amino acids. Examples of active peptides are glutathione, bradykinin, 
angiotensin, vasopressin and oxytocin [4].
Protein is a macromolecular and high molecular weight polypeptide, which 
is made up of long-chain amino acids (more than 50) arranged in a linear chain 
through peptide bonds [50]. It can exist in four different structural conformations 
such as primary, secondary, tertiary, and quaternary. The formation of these struc-
tures is dependent on the intermolecular interaction between functional groups of 
amino acids [51], through covalent bonds or non-covalent bonds.
The covalent bonds are strong bonds which include peptide bonds and disulfide 
bonds [51]. Peptide bonds are interactions between two consecutive amino acids 
through amino and carboxyl groups. Meanwhile, disulfide bonds link two cysteine 
residues through sulphhydryl groups [52].
On the other hand, non-covalent bonds are weak bonds that include hydrogen, 
electrostatic and hydrophobic bonds. Hydrogen bonds link two different peptides 
with the hydrogen atom of the N-H group and oxygen of the carboxylic group. 
Hydrophobic bonds will occur if the hydrophobic nature between non-polar side 
chains of amino acid interacts with each other [51].
3. Oral peptide delivery
The physiological barriers in the GIT responsible for protecting the body 
from the entry of pathogens. These barriers may reduce the bioavailability of the 
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protein. The barriers aforesaid include biochemical, cellular, and mucus barriers 
(Figure 4) [53].
The entire GIT has been coated with mucus. Mucus also promotes a physical 
barrier between the lining of epithelial and lumen [54]. It contains mucin protein 
which secretes proteolytic enzymes and traps peptide drugs through electrostatic 
interaction [55].
The epithelium of the GIT consists of an intestinal epithelial stem and microfold 
cells (M-cell) [48]. These cells are responsible for controlling protein uptake from 
the gut lumen into the bloodstream. Since protein drug is a macromolecule, the 
presence of protein complexes between adjacent epithelial cells prevents paracel-
lular transport of drug [56]. Meanwhile, transcellular transport is limited only to 
highly lipophilic molecules, unless the transportation is mediated by P-gp [57].
Figure 4. 
Physiological barriers to oral protein and peptide delivery (adapted from [53]).
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Due to the physical and chemical instability of protein in the GIT, they would 
not achieve an acceptable therapeutic bioavailability. The nature of the GIT as great 
physiology to digest food will be a barrier for protein drugs to penetrate through 
the membrane. The challenges and strategies to improve the protein drug delivery 
through oral administration need to be considered to ensure the drug achieves 
adequate therapeutic concentration in the body [58].
3.1 Challenges in oral peptide delivery
3.1.1 The presence of proteolytic enzyme and pH of GIT
GIT is the hollow organs include the oral cavity, stomach, small intestine, large 
intestine, and colon. Each part of the GIT is varying in pH. However, most proteins 
are stable at neutral pH and tend to undergo protein denaturation at the extreme 
changes in pH [48]. A building block of protein is sensitive to pH. In the presence of 
hydrochloric acid in the stomach, hydrolysis will occur and the disulphide bonds of 
peptide will be reduced.
Acidic pH environment activates the conversion of pepsinogen into pepsin 
[59], by transferring hydrogen ion (H+). Pepsin is responsible for the breakdown 
of peptide bonds which will interfere with the structure and stability of the 
peptide [59].
In the small intestine, the pancreatic juice is secreted in the duodenum. This 
juice contains pancreatic enzymes and bicarbonate ions (HCO3
−) [48]. The pancre-
atic enzymes consist of amylase, lipase, and protease, which are responsible for the 
digestion of lipid and peptide. Protease catalyses the proteolysis rate, which cleaves 
peptide bonds through hydrolysis [4, 58].
The presence of chymotrypsin and peptidase in the jejunum interferes with pep-
tide absorption in the epithelial membrane [48]. Peptide drugs are digested before it 
reaches the membrane and the fraction of the undigested peptide will reduce. This 
physiological function will lower the possibility for the therapeutic concentration of 
peptides to be achieved in the systemic circulation [58].
3.1.2 The intestinal barrier to drug absorption
The layers of the epithelial cell of the intestine are covered by mucus or mucin 
glycoproteins [55]. These glycoproteins will form a gel layer that covers the surface 
of the intestinal cell. The diffusion rate for the peptide to the epithelial membrane is 
restricted in the presence of mucus [54].
One of the intestinal mucosal epithelial cells is the goblet cell. Goblet cells 
are responsible for secreting mucin 2 in the intestine and Mucin-5b in the colon. 
Lubricate the passage for chime is the main function of the mucus layer, protecting 
the epithelium from mechanical damage of GIT [54].
The overexpression of mucin will interfere with the pharmacokinetics of drugs. 
The higher the concentration of the mucin, the lower the ability of a drug to diffuse 
through the membrane. Drugs and mucin interact through hydrophobic and Van 
der Waals interaction.
Large amounts of enzymes present within the mucus layer increase the tendency 
to digest peptide drugs [58]. The ionic strength, pH, and chyme content in the 
intestine will affect the charge density in the mucin [54]. The presence of a charged 
group on mucin interact ionically with charged particles and immobilised them in 
the mucus. The immobilisation of peptides leads to the clearing from the tract when 
the layer of mucus is shed [60].
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3.1.3 Tight junctions between adjacent epithelial cells
Tight junctions are protein complexes that existed within the adjacent epithelial 
cells [48]. It prevents leakage and restricts the flux of substances through the para-
cellular pathway [61]. They consist of transmembrane protein with extracellular 
domains called Claudin 4 (CLDN4). CLDN4 protects the paracellular physiological 
function of GIT [62].
The linkage of CLDN4 domains with zonula occludens 1 will result in the con-
nection of cytoskeleton components through linker protein [62]. The components 
include actin, myosin and microtubules which involve in the contraction of muscle, 
upon phosphorylation. The contraction leads to cellular tightness, hence, reduce the 
permeability of substance into the cell.
3.2 Strategies to improve oral peptide delivery system using chitosan
The effective delivery of oral peptide drugs can be achieved by altering the formu-
lation for maximum solubility, avoid enzymatic degradation and enhance the absorp-
tion of drugs through the intestinal epithelial cell [63]. For the sake of preventing 
enzymatic degradation or inactivation, the addition of enzyme or protease inhibitor 
is a great approach (Figure 5). Proteolytic enzymes are responsible for cleaving pro-
tein molecules into an inactive amino acid chain. Protease inhibitors such as aprotinin 
and chromostatin can be used to prevent the inactivation of protein drugs [7].
As discussed earlier, protein molecules show poor permeability through various  
mucosal surfaces and biological membranes. The improvement of membrane 
permeability can be achieved by the inclusion of a permeation enhancer into the 
formulation. Permeation enhancers are either tight junction selective or membrane 
perturbing [61].
Chitosan and its derivatives have been used as an enzyme inhibitor, permeation 
enhancer and mucoadhesive agent [30]. With the different mechanism, modifica-
tion, and preparation technique, this polymer also involves in the encapsulation of 
peptide drugs into the nanoparticulate system [60], which protect them from harsh 
GIT environment.
Figure 5. 
Strategies to improve oral peptide delivery system (adapted from [53]).
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3.2.1 Enzyme inhibition
There are two types of protease, including serine protease and Zn2+-dependent 
protease. Serine proteases, such as trypsin, chymotrypsin and elastase are pan-
creatic digestive enzymes. Meanwhile, Zn2+-dependent protease such as matrix 
metalloproteinase is an insulin-degrading enzyme [64]. Some enzyme inhibitors 
need chitosan to enhance their anti-protease activity and minimise peptide drug 
degradation [64]. For example, chymostatin is a protease inhibitor selectively to 
chymotrypsin-like serine proteases. This inhibitor will covalently be linked to the 
amino group of chitosan.
The active site of matrix metalloproteinase, such as carboxypeptidase, 
contains Zn2+ binding motif. It requires Zn2+ to promote nucleophilic attack by 
water. This protease cleaves membrane-bound pre-proteins of the cell to release 
cytokine. The ethylenediaminetetraacetic acid (EDTA) is a complexing agent 
that is capable of forming a complex with Zn2+ and retard the nucleophilic attack 
of water on carboxypeptidase. To inhibit the Zn2+-dependent protease, the 
EDTA is covalently bound to the primary amino groups of the chitosan-inhibitor 
conjugate [27, 65].
Moreover, the study showed that the effect of trypsin inhibitors would be dis-
rupted after the gastric phase. Therefore, the encapsulation of the peptide drug and 
trypsin inhibitor with chitosan-EDTA conjugates improve the controlled release of 
the molecules.
3.2.2 Chitosan as a mucoadhesive agent
Chitosan derivatives improve the permeation of water-soluble drug molecules 
due to their ability to adhere to the mucus [30]. Thiolated chitosan shows a greater 
effect in improving drug permeation through the cell membrane. With the forma-
tion of disulfide bridges, the thiol group of chitosan interacts with the cysteine-rich 
subdomains of mucus and allows greater mucoadhesion. Thus, the absorption of 
the peptide drug molecule increases with residence time [30].
It is worth noting that chitosan with a low degree of acetylation and high 
molecular weight leads to high charge density. The higher positive charge density of 
chitosan will bind to negatively charged tight junction channels. Ion displacement 
occurs, leading to intracellular spaces loosening [16].
The integrity and permeability of tight junctions can be illustrated with tran-
sepithelial electrical resistance (TER). The ability of TMC [66] and carboxymethyl 
chitosan [67] in decreasing the TER will increase the permeability of peptide drugs. 
TMC has been used to formulate buserelin, a synthetic peptide analogue for LHRH 
agonist, by the oral delivery system [68].
Thiolated chitosan, such as glutathione, cysteine and N-acetylcysteine, have 
strong mucoadhesive properties due to covalent bonding with cysteine-rich 
subdomains of the mucus glycoprotein. For chitosan-glutathione, this derivative 
improves chitosan stability, enhanced mucoadhesion and permeation enhancing 
effect. This system has been applied to the oral delivery of immunostimulant drug, 
thymopentin [30].
Chitosan-cysteine shows similar mucoadhesive but improved cohesion as 
compared to unmodified chitosan. The cohesiveness of polymeric drug formula-
tion is crucial to ensure the stability of the drug and will be released in a controlled 
manner. Furthermore, chitosan-N-acetylcysteine produces a longer retention time 
than unmodified chitosan. However, no drugs have been tested yet for these two 
chitosan derivatives [30].
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3.2.3 Encapsulation of peptide into the nanocarrier
By encapsulating peptides into a nanoparticulate system, enzymolysis and 
peptide aggregation can be avoided. This approach enhances the absorption of 
peptide drugs through the transmembrane of the small intestinal epithelium [69]. 
Nanoparticle will provide controlled-release properties in the presence of chitosan 
as a polymer. This condition will reduce repetitive dose administration and improve 
drug bioavailability [43]. In the presence of chitosan as a mucoadhesive agent, the 
retention time between formulation and absorption site will be maximised.
Cyclosporine is a cyclic peptide drug used to suppress the immune system, 
after organ transplantation. Cyclosporine with high molecular weight (1.32 kDa) 
shows poor bioavailability with low permeability through the biological barrier. 
Conventional oral cyclosporine has been shown to have an unpredictable low 
therapeutic concentration in the bloodstream.
Therefore, a nanoparticle drug delivery system is a promising strategy to 
improve the oral bioavailability of cyclosporine. Chitosan nanoparticles in the 
presence of tripolyphosphate, as a cross-linker, make it more convenient as com-
pared to conventional ones. The bioavailability of the nanoparticulate cyclosporine 
increases by 73% [69]. Exendin-4 is a glucagon-like peptide-1 receptor agonist that 
has been approved to control type 2 diabetes mellitus. This peptide drug has high 
susceptible to enzymatic degradation [70]. Chitosan-tripolyphosphate conjugated 
nanoparticle was used to design oral suspension and enteric-coated capsules of 
exendin-4 to increase the bioavailability of exendin-4 slightly.
3.2.4 Efflux pump inhibition
Efflux pump is a membrane protein located within the cytoplasmic membrane 
of a cell. It translocates a variety of substrates across extra- and intra-cellular 
membranes. Multidrug efflux pump can be one of the drug resistance mecha-
nisms, as it pumps foreign substances (or drugs) out of cells. This active process is 
an ATP-dependent [71].
P-glycoprotein (P-gp) is a transmembrane glycoprotein and the best example of 
a multidrug efflux pump. It is expressed and located in the intestinal epithelium, 
liver cells and proximal tubule cells of the kidney. P-gp is also located within the 
blood–brain barrier (BBB), which provides an obstacle for drugs to enter the region. 
Therefore, it must be difficult for antipsychotic drugs to bypass BBB and exert their 
effect [57, 71, 72].
Chitosan may enhance drug permeation by opening of tight junctions which is 
highly related to CLDN4 [73]. Chitosan will modulate CLDN4 protein redistribu-
tion to the cytosol and disrupt tight junctions [62]. This phenomenon will enhance 
paracellular permeability and reduce TER. Thus, declining barrier function of 
epithelial cells to allow drugs to enter the cell [74].
Furthermore, the use of thiolated chitosan (thiomer) has shown to be useful in 
bypassing the P-gp. The thiol-moiety of thiolated chitosan may allow the formation 
of disulfide bonds between the cysteine groups of the P-gp [9]. The thiomers then 
enter the channels of the P-gp pump together with the therapeutic agent, which 
obstruct the function of the multidrug efflux pump [57].
For infectious disease by Gram-negative bacteria, chitosan plays an important 
role in facilitating effective delivery of antimicrobials to the infection site [15, 49]. 
Chitosan will encapsulate drugs and carry them into bacterial cells by attraction 
forces between polycationic chitosan and negatively charged bacteria [49]. This 
action avoids the efflux pump at the cell membrane of the bacterial cell.
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4. Oral vaccine delivery system
Vaccination is one of the most cost-effective approaches to prevent infectious 
diseases such as hepatitis B, tetanus, polio, and rabies. Vaccines contain pathogens, 
either live-attenuated, inactive or killed antigen [75]. These pathogens will be 
administered in the body and recognised by the immune system.
The oral delivery of vaccines is quite challenging as the pathogen is introduced 
into the body. It is mandatory to ensure mucosal immune response works effectively 
to protect the body against the pathogen and their toxin [54].
As the vaccine enters the intestine, its presence will trigger the inductive site, 
the Peyer’s patches. The Peyer’s patches consist of M-cell which will allow the entry 
of the antigen through endocytosis. The antigen then will be transported into 
intraepithelial dendritic cells or macrophages and be taken up by the cell through 
phagocytosis [76].
The antigen-loaded dendritic cell will present the antigen fragment on its 
surface and triggers the activation of naive CD4+ T-cells. The activated CD4+ T-cells 
will bind to the antigen fragment, MHC class II. This binding releases chemical 
mediators, interleukin-2 (IL-2), that function to regulate the activity of lympho-
cytes for immunity. IL-2 stimulates the cell division of CD4+ T-cells, activates 
B-cells and cytotoxic T-cells. B-cell is responsible for mediating humoral immunity 
by differentiating into plasma cells. Plasma cells will generate antibodies to fight 
against pathogens [77].
5. Challenges in oral vaccine delivery system
Viral protein requires the right structural conformation to attach to the host cell 
and replicate. Highly acidic in the stomach and extreme temperature changes will 
cause protein denaturation. The denaturation of the virus will alter the conforma-
tion of its structure [58]. The high temperature will break the phosphodiester bond. 
However, at low temperature, the degradation of the nucleic acid will also lead to 
viral inactivation [78].
Furthermore, to transport vaccines orally, it should be able to overcome the 
biological barrier of the intestinal epithelial cell such as tight junction and mucus. 
The hydrophilic antigen cannot cross the phospholipid bilayer to enter systemic 
circulation due to the function of tight junction in controlling the permeability of 
the membranes. Therefore, the uptake of the antigen to mucosal tissue is limited 
with a short time of exposure [78].
The GIT contains normal flora or microbiota which help in maintaining 
the structure of the gut mucosal barrier [55]. Those microbiotas not only aid 
nutrient metabolism, but they also possess an action to protect against invading 
pathogens [79, 80]. Well-balance microbiota is needed to induce the effective-
ness of vaccines through oral administration. The delivery of the vaccine will 
be interrupted in patients with microbiota dysbiosis, leading to blunted vaccine 
response [80].
The induction of danger signals appropriately by the vaccine is essential to 
trigger an immune response [81]. Due to these limitations, there is a problem 
in inducing an adequate immune response against administered pathogens [3]. 
Consequently, a higher and repetitive dose is required. Nevertheless, the admin-
istration of high antigen doses repetitively may develop systemic oral tolerance 
towards vaccines [3, 78].
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6. Strategies to improve oral vaccine delivery system using chitosan
The uptake of antigen by immune cells depends on the particle size of the antigen. 
The smaller size of pathogens is readily taken up by dendritic cells [75]. The same 
goes for peptide, encapsulation of pathogens in nanoparticles is a good approach to 
improve the effectiveness of vaccines in stimulating the immune system [75].
Small particle size is required to penetrate the mucus. The formulation will be 
excluded out from the layer of mucus if particle size greater than normal mucus 
pore size (100–500 nm). This leads to the interruption in the bioavailability of 
antigen to targeted antigen-presenting cell (APC). Therefore, the development 
of nanoparticulate systems is required to provide a smaller size (20 – 40 nm) of 
formulation [82].
Medium molecular weight chitosan (MMWC) with the degree of deacetylation 
of 85% has been shown to improve the delivery of ovalbumin antigen with the 
presence of alginate and calcium phosphate (CaP). CaP has adjuvant properties by 
activating the surface expression of B-cell. CaP can be coated with mucosal pene-
trating polymers, such as chitosan and alginate to avoid biodegradation by enzymes 
present in the GIT [82]. In the stomach, the alginate-chitosan-coated CaP nanopar-
ticle delays the release of ovalbumin antigen. The antigen then will be released in 
the intestine and colon with a sustained-release mechanism. This nanocarrier has 
successfully encapsulated ovalbumin antigen with small size (< 50 nm) [82].
The antigen should be transported to the intestine and directly to the M-cell of 
the Peyer’s patches [6]. Chitosan develops well-protected mucoadhesion by pro-
longing the residence time at mucosal surfaces. The uptake of antigen by epithelial 
cells of the intestine will be improved by chitosan. An increase in the activity of 
macrophages will improve the secretion of mucosal IgA and IgG [76].
7. Conclusions
Chitosan-based drug formulation has gained attention for their ability to serve as 
a carrier and an enhancer for oral delivery of peptides and vaccines. Although oral 
delivery is the most convenient and preferred route of administration, however, it 
has limitations due to the presence of the proteolytic enzyme, pH of GIT and the 
intestinal barrier to drug absorption. In recent years, there has been considerable 
research interest in the application of chitosan as an enzyme inhibitor, mucoadhe-
sive agent and efflux pump inhibitor. Interaction of positively-charged amino groups 
of chitosan with negatively-charged sialic acid groups that exist in mucin prolongs 
the residence time between drugs and membranes, therefore enhancing the bioavail-
ability of the drugs. Other formulation strategies include encapsulation of proteins, 
peptides and vaccines into a nanoparticulate delivery system. By encapsulating 
peptide into a nanocarrier system, the enzymolysis and peptides aggregation can be 
avoided thus enhances the absorption of peptide drugs in the intestinal epithelium. 
Similarly, encapsulation of pathogens in nanoparticles is a good approach to improve 
the effectiveness of vaccines in stimulating the immune system.
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